Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus rituximab maintenance versus rituximab maintenance after lenalidomide-rituximab induction in relapsed/refractory indolent or mantle cell lymphoma
2017-002290-19Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide and rituximab in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and mantle cell lymphoma (MCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Jul 2017; status: completed.
02
Drugs
lenalidomiderituximab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2017-002290-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002290-19.